WT1 and myelodysplastic syndrome: In phase I trial of refractory AML and high-risk MDS patients (n=8), adoptive transfer of WT1-specific TCR-T cells did not confer adverse events and the TCR-T cells persisted throughout the study period with retained WT1-specific immune reactivity in majority of the patients (148).